Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009
NCT00734734 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64
Last updated 2016-01-28
Summary
Trial for annual approval of interpandemic influenza vaccines
Conditions
- Interpandemic Influenza
Interventions
- BIOLOGICAL
-
Seasonal Influenza Vaccine
1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
Sponsors & Collaborators
-
Novartis Vaccines
lead INDUSTRY
Principal Investigators
-
Novartis Vaccines · Novartis Vaccines
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-06-30
- Primary Completion
- 2008-07-31
- Completion
- 2008-07-31
Countries
- Italy
Study Locations
More Related Trials
-
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects
NCT00748150 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
NCT00434733 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
NCT01651104 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009
NCT00748813 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects
NCT00518726 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
NCT00329966 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.
NCT00316628 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
NCT00311480 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects
NCT01161264 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
NCT00342940 ·Status: WITHDRAWN ·Phase: PHASE2
-
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
NCT01342796 ·Status: COMPLETED ·Phase: PHASE2
-
Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine
NCT01010893 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects
NCT00522236 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
NCT01459276 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults
NCT01389479 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules
NCT00848029 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model
NCT03180801 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
NCT01879540 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.
NCT00316615 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects
NCT00956449 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects
NCT00841646 ·Status: COMPLETED ·Phase: PHASE2
-
A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older
NCT01222403 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
NCT00841763 ·Status: COMPLETED ·Phase: PHASE3
-
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season
NCT01633749 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 1b Influenza Vaccine Study in Healthy Subjects
NCT01181336 ·Status: COMPLETED ·Phase: PHASE1